

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERA

NERPHARMA

SIMIS

NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries

Nerviano, 17 January 2022

The Shareholders' Meeting of NMS Group S.p.A. (the "Company") has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato.

Following the Shareholders' Meeting, the Company's newly formed Board of Directors approved a new governance to accelerate the progression of the portfolio, to strengthen the competitive positions of Accelera and NerPharMa, and to optimize and deliver concrete values for its patients, shareholders, employees and community. Dr. Hugues Dolgos, a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology, was appointed as Chief Executive Officer ("CEO") of the Company, effective immediately.

Dr. Dolgos joins from Servier where he was Global Head of Oncology and a member of the R&D leadership team. Prior to that, he held notable positions at Merck KGaA as Vice President and Head of R&D Strategy PMO, Quantitative Pharmacology and Drug Disposition, setting up strategic directions to best select and ultimately deliver candidate drugs even beyond approval. During the past decades, he has been leading large teams at international top-tier companies like AstraZeneca and Merck KGaA on R&D strategy, R&D governance and capabilities building including Modeling&Simulation, DMPK, Clinical Pharmacology, Bioinformatics, R&D digital, forming alliance, driving changes and creating values for the organizations. In his role, the CEO will focus on the execution of all the activities required to foster the Company's growth and to enhance its R&D capability.

"I feel privileged to take up the CEO role and to lead the Company reaching its strategic goals and the next sets of milestones, and I truly honor the confidence the Board of Directors have placed in me," commented Dr. Dolgos. "NMS Group is well known for its experienced team and substantial achievements in bringing molecules for example entrectinib and encorafenib into marketed drugs. I am looking forward to working closely with colleagues and our global partners to ensure that we keep delivering innovative cancer therapies and improve patients' lives all over the globe" added Dr. Dolgos.

The Shareholder's Meeting has also set up the new governance structures of the subsidiaries, and granted all the necessary powers to the newly appointed Board of Directors and chief executives respectively:

Nerviano Medical Sciences S.r.l.

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERA

NERPHARMA

SIMIS

Board members: Hugues Dolgos (Chairperson), Guoxian (Gregory) Wu and Barbara Marengo
CEO: Guoxian (Gregory) Wu

Accelera S.r.l. and NerPharMa S.r.l.

Board members: Hugues Dolgos (Chairperson), Angelo Colombo and Enrico Pesenti
CEO: Angelo Colombo

SIMIS S.r.l.

Sole Director: Giuseppe Vivolo

The Company would also like to warmly thank all the members of the Board and executives whose terms of office ended today for their work and commitment in performing their duties in the best interests of the Company and of all its stakeholders.

###

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

The NMS Group has three subsidiaries. NMS Srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

BOD and CEO Profiles

Hugues Dolgos - CEO of NMS Group S.p.A / Chairperson of Nerviano Medical Sciences S.r.l., Accelera S.r.l. and NerPharMa S.r.l.

Hugues Dolgos is a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology. Dr. Dolgos joins from Servier where he was Global Head of Oncology and a member of the R&D leadership team. Prior to that, he held notable positions at Merck KGaA as Vice President and Head of R&D Strategy PMO, Quantitative Pharmacology and Drug Disposition, setting up strategic directions to best select and ultimately deliver candidate drugs even beyond approval. During the past decades, he has been leading large teams at international top-tier companies like AstraZeneca and Merck KGaA on R&D strategy, R&D governance and capabilities building including Modeling&Simulation, DMPK, Clinical Pharmacology, Bioinformatics, R&D digital, forming alliance, driving changes and creating values for the organizations. Dr. Dolgos is also a Board member of Skymab.

He holds a Doctor of Pharmacy degree from the University of Pharmacy (Paris V), a Post Graduate degree of Analytical Chemistry (DEA) from University Pierre & Marie Curie (Paris VI) and an MS in Medical Sciences from Paris V and Paris VI Universities.

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERA

NERPHARMA

SIMIS

Tak-Wai (David) Wong – Chairperson of NMS Group S.p.A. / Partner and Co-Head of Private Equity of PAG Asia Capital

David Wong is a Partner based in Shanghai and co-head of PAG Asia Capital's Private Equity strategy (PAGPE). Prior to joining the Group in 2011, Mr. Wong worked with TPG Capital, where he was responsible for the sourcing, evaluation and execution of buyout and significant minority opportunities in Asia. Mr. Wong also assumed interim CFO responsibilities at China Grand Auto and interim management roles at Nissin Leasing. Prior to that, he was with Lotus Capital, a domestic Chinese private equity manager focused on growth capital investments in China. Mr. Wong spent six years with Morgan Stanley based in San Francisco and Hong Kong.

Mr. Wong serves on the Board of Directors of multiple companies including AirPower Technologies, Golden Apple Education, Mobvista, Nayuki Tea, Sinopharm Leasing, Yinglian Pharma, and Zhenai.com.

He holds a Bachelor of Arts degree and a Bachelor of Science degree from the University of California, Berkeley.

Raj Sundar - Board member of NMS Group S.p.A. / Executive Director of PAG Asia Capital

Raj Sundar is an Executive Director with PAG Asia Capital. He has over 20 years' experience in general management and strategy consulting. Prior to joining PAG in 2020, Mr. Sundar was the Managing Director (ASEAN) at Kimberly-Clark, where he was responsible for delivering overall P&L growth for the business, leading a team of ~2,000 people. Prior to that, he worked as a strategy consultant with The Boston Consulting Group and with Unilever in sales and marketing roles.

At PAG, he works closely with the Boards and Management teams of several of PAG's portfolio companies across the world, and drives value creation efforts at these companies. His portfolio includes PAG's investments across the healthcare, consumer and industrial goods sectors.

He holds an MBA from the University of Chicago and an Engineering Degree with Honors from the Indian Institute of Technology.

Jianghua (Peter) Zhao – Board member of NMS Group S.p.A. / Managing Director of V-Capital

Peter Zhao is in charge of the healthcare investment in V-Capital. Mr. Zhao has over 20 years of experience in industrial operation, investment and financing. His accumulated asset under management exceeds 5 billion RMB. Prior to join V-Capital, Mr. Zhao successively served as Director of President's office at three-nine Group (Stock code: 000999), Vice President of Huali Group, Chairman of Wuhan Jianmin Pharmaceutical Group (600976), Director of Kunming Pharmaceutical (600422), Director of Huali Pharmaceutical (000607), senior partner of Hongyi Investment Group, and Executive Partner of Shanghai Hongxing Hongyi VC Fund.

He holds a Bachelor of Science degree from China Pharmaceutical University and a Master degree from Guanghai Management School of Beijing University.

Liping Meng – Board member of NMS Group S.p.A. / Director of V-Capital

Liping Meng has 10 years of experience in research, project management, investment. Prior to join V-Capital, Dr. Meng was a senior manager of Shanghai Pudong Science and Technology Investment Co., Ltd. where she focused on cross-border M&A. Before that, she was a manager at China State Institute of Pharmaceutical Industry, a center research subsidiary of Sinopharm Group, where she was in charge of international collaboration and research project management.

She holds a Bachelor of Science degree from Fudan University and a Doctorate degree in Immunology from North Carolina State University.

Massimiliano Amato – Board member of NMS Group S.p.A. / Member of Board of Statutory Auditors of the ASST in Busto Arsizio

Massimiliano Amato is a member of the Board of Statutory Auditors of the ASST in Busto Arsizio (VA), a key healthcare institution in the Lombardy Region and holds key roles in governing other important healthcare organizations. Prior to that, he was Chairman of the Board of Statutory Auditors of ATS Insubria and Chairman of the Board of Statutory Auditors ALER of Varese, Como, Busto Arsizio and Monza. He is a Professional Chartered Accountant enrolled in the Professional Chartered Accountants Register (Dottori Commercialisti) of Varese and in the Registered of Accounting Auditors (Revisori Contabili) of the Italian Ministry of Justice.

Guoxian (Gregory) Wu – CEO and Board member of Nerviano Medical Sciences S.r.l.

Guoxian Wu serves as Chief Executive Officer and member of the Board of Directors at Nerviano Medical Sciences (NMS S.r.l.) since 2018. Dr. Wu leverages more than 20 years of global biopharmaceutical experience and leadership, as well as years of academic experience as a faculty member at Fudan University. He is co-founder of Lyrea Therapeutics and Xian-Feng Pharmaceuticals. Prior to Lyrea Therapeutics, he held positions of increasing responsibility with Plexxikon-a Daiichi Sankyo company, Sugem-Pharmacia, Renovis and Coulter-Corixa. He has made significant contributions to drugs garnering regulatory approval including Pexidartinib and Vemurafenib, as well as contributions to teams in launching Sunitinib and Tositumomab. He holds a PhD in Organic Chemistry from Princeton University, an MS in Organic Chemistry and a BS in Chemistry from Fudan University.

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERERA

NERPHARMA

SIMIS

Barbara Marengo – Board member of Nerviano Medical Sciences S.r.l.

Barbara Marengo has multi-disciplinary experiences in the Administration, Finance and Control for over 25 years and of which more than half were dedicated to keep Nerviano Medical Sciences S.r.l. a solid and sound organization. She holds a degree in Economics and Commerce from the University of Turin.

Angelo Colombo – CEO and Board member of Accelerera S.r.l. and NerPharMa S.r.l.

Angelo Colombo has over 30 years of experience in the pharmaceutical field, gained both in the context of multinationals such as Pfizer, Schering-Plough, Pharmacia, and in important CDMOs like Corden Pharma. He holds a Bachelor of Science degree in Chemistry and Pharmaceutical Technologies obtained at the University of Milan.

Enrico Pesenti – Board member of Accelerera S.r.l. and NerPharMa S.r.l.

Enrico Pesenti has profound understanding and decades of experience in R&D of discovery and preclinical studies of new drugs. He holds a DVM (Doctor Veterinary Medicine) Degree at the University of Milan, a Dost-Doctoral Diploma in Hygiene and Prophylaxis of Infectious Diseases at University of Milan, and a Post-Doctoral Diploma in Pharmacological Research at Mario Negri Institute of Pharmacological Research, Milan, Italy.

Giuseppe Vivolo – Sole Director of SIMIS S.r.l.

Giuseppe Vivolo is the Sole Director and Technical Director SIMIS S.r.l. since 2013. During his nearly 40 years of professional experience, he held key positions in the energy services sector (ESCO) and facility management in national and international groups, both in the public and private sectors.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it